Abiopharma

Appendix 3Y for Lyn Cobley

Teva Pharmaceutical Industries Ltd. - Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva Pharmaceutical Industries Ltd. - Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Guardant Health, Inc. - Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition